Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld
Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, […]
Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, […]
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – […]
AstraZeneca’s Covid-19 antibody drug Evusheld reduced the risk of infection by 83% after six months. These results published in the New England Journal of Medicine […]
GlaxoSmithKline and Vir’s Xevudy has become the latest COVID-19 antibody therapy to have its use restricted by the FDA as a result of waning activity […]
AstraZeneca confirmed today that it has discontinued clinical development of a follow-up to its COVID-19 vaccine Vaxzevria targeted at the Beta variant of the virus, […]
The antibody drug, Evusheld, was found to be strongly effective in preventing Covid in a clinical trial that enrolled mostly those at high risk.
The antibody drug, Evusheld, was found to be strongly effective in preventing Covid in a clinical trial that enrolled mostly those at high risk.
The antibody drug, Evusheld, was found to be strongly effective in preventing Covid in a clinical trial that enrolled mostly those at high risk.
Copyright © 2024 | WordPress Theme by MH Themes